Drug Profile
Research programme: inhaled peptide therapeutics - Lung Biotechnology/mondoBIOTECH
Alternative Names: DasKloster 0138-01Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Lung Rx; mondoBIOTECH
- Developer Lung Biotechnology; mondoBIOTECH
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis; Lung disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA (Inhalation)
- 01 Apr 2011 Preclinical trials in Cystic fibrosis in USA (unspecified route)